Express Pharma

India is a key focus country under renewed global strategy

0 485

Sandra de Wild Charonnens, Strategic Advisor, Life-Science & Health, NFIA, informs
why the Netherlands is an attractive destination for India’s life sciences companies
with its attractive business climate and wide-ranging scope for innovation, in an
exclusive interaction with Sanjiv Das

What type of opportunities is Netherlands offering to pharma companies, making it an attractive market?
The Netherlands is Europe’s densest and most innovative life sciences and health community. The country’s central geographic position, combined with its accessibility and excellent infrastructure, makes it the location of choice to 2,900 life science and medical technology companies and research organisations, employing over 34,000 people, University Medical Centre’s and research organisations.

Together with leading multinationals such as Janssen, MSD, Boston Scientific, Abbott, Amgen, GlaxoSmithKline, Medtronic, Pfizer, Novartis — the Netherlands boasts one of the most concentrated life sciences regions in the world within a 200 km radius. Their operations include R&D, production to logistics and marketing. Some have established their European Headquarters in the Netherlands or have invested in Dutch SMEs.

Dutch companies hold strong positions in the fields of molecular imaging, medical informatics, biopharma, human and veterinary vaccines, regenerative medicine and biomaterials, medical technology, and health infrastructure.

The Netherlands provides an attractive business climate with wide-ranging scope for innovation. It is known for its competitive and stable tax regime, attractive R&D incentives, excellent research facilities and top-rated educational institutions that result in a well-educated and multilingual workforce with a high level of productivity.

How many of these pharma and healthcare companies are based out of India?
Currently, there are over 18 leading Indian pharma giants that